It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The molecular mechanisms of excitation/inhibition imbalances promoting seizure generation in epilepsy patients are not fully understood. Evidence suggests that Pannexin1 (Panx1), an ATP release channel, modulates the excitability of the brain. In this report, we performed electrophysiological, behavioral, and molecular phenotyping experiments on zebrafish larvae bearing genetic or pharmacological knockouts of Panx1a and Panx1b channels, each homologous to human PANX1. When Panx1a function is lost, or both channels are under pharmacological blockade, seizures with ictal-like events and seizure-like locomotion are reduced in the presence of pentylenetetrazol. Transcriptome profiling by RNA-seq demonstrates a spectrum of distinct metabolic and cell signaling states which correlate with the loss of Panx1a. Furthermore, the pro- and anticonvulsant activities of both Panx1 channels affect ATP release and involve the purinergic receptor P2rx7. Our findings suggest a subfunctionalization of Panx1 enabling dual roles in seizures, providing a unique and comprehensive perspective to understanding seizure mechanisms in the context of this channel.
The Panx1a and Panx1b (pannexin) ATP release channels exhibit pro- and anti-convulsant effects, respectively, in a zebrafish model, providing further insight into the role of pannexins in seizure development.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 York University, Department of Biology, Toronto, Canada (GRID:grid.21100.32) (ISNI:0000 0004 1936 9430); York University, Center of Vision Research (CVR), Toronto, Canada (GRID:grid.21100.32) (ISNI:0000 0004 1936 9430); Krembil Research Institute, University Health Network, Toronto, Canada (GRID:grid.231844.8) (ISNI:0000 0004 0474 0428)
2 York University, Department of Biology, Toronto, Canada (GRID:grid.21100.32) (ISNI:0000 0004 1936 9430); York University, Center of Vision Research (CVR), Toronto, Canada (GRID:grid.21100.32) (ISNI:0000 0004 1936 9430)
3 Krembil Research Institute, University Health Network, Toronto, Canada (GRID:grid.231844.8) (ISNI:0000 0004 0474 0428); University of Toronto, Department of Medicine, Physiology and BME, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
4 York University, Department of Biology, Toronto, Canada (GRID:grid.21100.32) (ISNI:0000 0004 1936 9430)